Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.PMID:38424308 | DOI:10.1007/s40262-024-01352-9

Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Joseph Piscitelli Micaela B Reddy Lance Wollenberg Laurence Del Frari Jason Gong Linda Wood Yizhong Zhang Kyle Matschke Jason H Williams Source Type: research